HSP90AB1 and breast cancer: In addition to Ganetespib, there are other second-generation Hsp90 inhibitors that are in preclinical or clinical testing in patients with BC, such as NVP-AUY922 (resorcinol derivative) [146], PU-H71 (purine derivative) [147], and other inhibitors of the benzamide class, including XL888.